Brief: Sheba Medical Center And Enlivex Announce Dosing Of The First Patient In Phase I/II Trial Evaluating Allocetra Combined With Chemotherapy
06/07/2022 13:42
July 6 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* SHEBA MEDICAL CENTER AND ENLIVEX ANNOUNCE DOSING OF THE
FIRST
PATIENT IN PHASE I/II TRIAL EVALUATING ALLOCETRA COMBINED WITH
CHEMOTHERAPY IN PATIENTS WITH PERITONEAL METASTASES ARISING FROM
SOLID CANCERS
Source text for Eikon: ID:nGNXcdwBhX
Further company coverage: ENLV.TA
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment